Pipeline
Blood cancers affect over 1.1 million people in the United States annually, with over 156,000 new cases estimated in 2014 alone.
- The only curative treatment is an allogeneic HSCT with less than a 50% success rate in patients with chemo-refractory disease
- Most patients lack sensitivity to currently available therapies
- Poor outcomes following allogeneic HSCT
- Current conditioning regimens are very toxic and have severe side effects that can be life-threatening
- Toxicity of conditioning is a limiting factor for wider use of HSCT for the treatment of both malignant and non-malignant diseases
- Toxicity of conditioning restricts the age range of potential recipients
- A novel third generation HEMO-CAR-T (Anti-FLT3 CAR-T cells) to eliminate malignancy in patients with FLT3+ R/R AML and potentially condition bone marrow transplant
- A novel bispecific monoclonal antibody CDX (FLT3-CD3) to eliminate malignancy in patients with FLT3+ R/R AML and potentially condition bone marrow transplant
After exhausting all options, including chemotherapy, radiation therapy and immunotherapy, Hemogenyx Pharmaceuticals seeks to tackle the dangers and limitations associated with the current standard of care with our revolutionary technology.
HEMO CAR-T
Efficacy – The antibody fragment of HEMO-CAR-T does not compete with the FLT3 Ligand (FLT3L) expressed by a variety of cell types on their surface including AML, avoiding possible reduction of HEMO-CAR-T efficacy due to competition
Market Expansion – Effective and non-toxic conditioning will extend the use of BM/HSC transplantation to older and more frail patients and potentially target several additional indications including autoimmune and rare genetic disorders
CDX
Efficacy – Anti-FLT3 ‘arm’ of CDX does not compete with the FLT3 Ligand expressed by a variety of cell types on their surface including AML, avoiding possible reduction of the antibody efficacy since no competition with endogenous ligand
Safety – CDX does not activate T cells in the absence of target cells.
Market Expansion – Effective and non-toxic conditioning will extend the use of BM/HSC transplantation to older and more frail patients and potentially target several additional indications including autoimmune and rare genetic disorders
Blue: scFv are anti-FLT3 portion of the bispecific antibody.
Red: anti-CD3 portion of the bispecific antibody